| Pros | Cons |
|---|---|
| Average 15–22% body weight reduction in clinical trials | Nausea, vomiting, diarrhea — especially early in titration |
| Meaningful reduction in food preoccupation (“food noise”) | Weight regain after stopping (~two-thirds of lost weight within 1 year) |
| Favorable effects on blood sugar, blood pressure, lipids | Potential lean mass loss without adequate protein and resistance training |
| Once-weekly injection — convenient dosing schedule | Small increased risk of pancreatitis and gallbladder disease |
| Robust cardiovascular outcome data in high-risk populations | Contraindicated in MTC/MEN 2 history; not appropriate during pregnancy |
What do GLP-1 receptor agonists actually do?
GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It signals satiety to the brain, slows gastric emptying, and supports insulin secretion in response to food. GLP-1 receptor agonists are compounds that activate those same receptors, extending and amplifying the natural GLP-1 signal.
The clinical result is a sustained reduction in appetite and food intake that most patients describe as a quieting of food noise — the constant background pull toward eating that many people with excess weight experience. That reduction in drive to eat, sustained over months, produces the meaningful weight loss seen in the major clinical trials.
Compounded semaglutide and tirzepatide, prepared by USA-based licensed 503A pharmacies and prescribed by licensed clinicians, are not FDA-approved drugs and are not interchangeable with branded products. They are individualized compounded medications prepared to a clinician’s specification.
What are the pros, and what does the evidence show?
Substantial, sustained weight reduction
The STEP 1 trial of weekly semaglutide found an average 14.9% reduction in body weight over 68 weeks compared to 2.4% with placebo. The SURMOUNT-1 trial of tirzepatide found up to 22.5% average weight reduction at the highest dose over 72 weeks. These are among the largest effect sizes ever documented for a pharmacological weight-management intervention — significantly exceeding older medications in the same class.
Reduced food noise and appetite
Beyond the scale, a consistent finding in patient-reported outcomes is a meaningful reduction in preoccupation with food. For people who have experienced chronic difficulty with overeating, many describe this as a qualitative shift in their relationship with food rather than just a quantitative change in what they eat.
Metabolic and cardiovascular markers
GLP-1 receptor agonists have shown favorable effects on blood sugar regulation, blood pressure, and lipid panels in clinical populations. Large cardiovascular outcome trials with branded GLP-1 medications have reported reductions in major adverse cardiovascular events in people with established cardiovascular disease and type 2 diabetes — effects that likely reflect both weight reduction and direct metabolic actions.
Once-weekly dosing convenience
Subcutaneous injections are administered once weekly, which contributes to adherence compared to daily medications. The dose is typically titrated slowly over weeks to months to minimize side effects, giving the body time to adapt.
The single most important caveat: GLP-1 medications appear to work primarily while you take them — about two-thirds of lost weight returned within a year of stopping in the STEP 1 extension.
What are the cons and side effects of GLP-1 medications?
Gastrointestinal side effects
The most common reason people discontinue GLP-1 therapy is GI intolerance. Nausea affects a substantial proportion of users, particularly in the early titration phase. Vomiting, diarrhea, and constipation are also reported frequently. For most people these diminish as the body adjusts, but for some they remain limiting. A slow titration schedule and attention to eating patterns (smaller meals, slower eating, avoiding high-fat foods that trigger more severe nausea) reduces the burden considerably.
Weight regain after stopping
The STEP 1 extension study is the most cited data point here: one year after stopping semaglutide, participants had regained on average about two-thirdsof the weight they had lost. This is the most important “con” for anyone considering these medications — they appear to work primarily while being taken. This isn’t unique to GLP-1 medications (weight regain after stopping most interventions is well-documented), but it is a real consideration for long-term planning.
Potential for lean mass loss
Rapid weight loss from any cause can include loss of lean muscle mass, not just fat. This risk is not unique to GLP-1 medications but is a real consideration. Resistance training and adequate protein intake are widely recommended by clinicians to minimize this effect during treatment. Ongoing research is examining how to optimize body composition outcomes alongside weight management.
Pancreatitis and gallbladder risk
GLP-1 receptor agonists carry a small but real increased risk of acute pancreatitis and gallbladder disease (cholelithiasis). These are uncommon but serious. Anyone with a personal or family history of pancreatitis or gallbladder issues should discuss these risks explicitly with their clinician before starting.
Contraindications
GLP-1 therapy is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also not appropriate during pregnancy. A thorough clinician intake screens for these and other relevant contraindications.
Who tends to benefit most
The evidence base is strongest for adults with a BMI of 30 or above, or those with a BMI of 27 or above with at least one weight-related comorbidity. Response varies significantly between individuals — some lose substantially more than the trial averages, some less. Non-response is real and worth acknowledging.
People who tend to do best are those who pair the medication with behavioral changes, including attention to nutrition quality, protein adequacy, and resistance training. The medication reduces the drive to overeat; the lifestyle work shapes what the body does with the resulting deficit.
The role of clinician supervision
No treatment decision is a good one without honest information. The pros of GLP-1 therapy are real and supported by robust trial data. The cons are also real and should be understood clearly before starting.
A clinician review assesses your specific history, current medications, and goals — and helps you weigh whether GLP-1 therapy is appropriate for you. At PepScribe, compounded semaglutide and tirzepatide are prescribed by licensed clinicians and prepared by USA-based licensed 503A pharmacies. No hidden overseas supply chain.
If you want to explore the options, a brief intake assessment connects you with a clinician who can review your situation and answer questions specific to your history.
Frequently asked questions
What are the main pros of GLP-1 receptor agonists?
The most evidence-backed benefits include significant reduction in body weight (typically 10–22% over 68–72 weeks in clinical trials), reduced appetite and food-noise, improved blood sugar regulation, and favorable effects on cardiovascular risk markers in certain populations. Compounded versions are prescribed by licensed clinicians and prepared in USA-based 503A pharmacies.
What are the most common cons or side effects of GLP-1 medications?
The most frequently reported side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are typically most prominent when starting or increasing the dose and tend to diminish over time. More serious but uncommon risks include pancreatitis and gallbladder issues. A clinician review is important to screen for contraindications.
How long do you have to stay on a GLP-1 medication?
Weight loss achieved on GLP-1 medications is largely maintained while taking them. Studies show that stopping the medication leads to significant weight regain for most people. A clinician can help you assess long-term plan and whether tapering or continuation makes sense for your goals.
Is compounded semaglutide the same as Ozempic or Wegovy?
Compounded semaglutide is not FDA-approved and is not the same as branded Ozempic or Wegovy. Compounded versions are prepared by licensed 503A pharmacies in the USA under clinician supervision. They are not interchangeable with branded drugs and should not be obtained without a licensed clinician's oversight.
Who is not a good candidate for GLP-1 therapy?
People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), those who are pregnant or nursing, and individuals with certain GI conditions may not be good candidates. A clinician intake screens for these exclusions.
Do GLP-1 medications cause muscle loss?
Some weight lost on GLP-1 therapy can include lean mass, particularly without resistance training. Research is ongoing into whether optimizing protein intake and exercise during treatment can preserve or build muscle mass. A clinician-supervised program accounts for this risk.